QS Pharma receives approval from European Medicines Agency for commercial manufacture
QS Pharma, a Quotient Clinical business, is now approved to manufacture medicinal products for the US, Europe and Japan.
How do I save >12 months of drug development time? Download the Tufts CSDD white paper
Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.
Ask us a question